TY - BOOK ID - 118996804 TI - Pandemic Medicine PY - 2022 SN - 9781685851033 PB - Boulder DB - UniCat KW - Drug development. KW - Drugs KW - Medical innovations KW - Medical policy. KW - POLITICAL SCIENCE / Public Policy / Science & Technology Policy. KW - Quality control. KW - Social aspects. KW - Health care policy KW - Health policy KW - Medical care KW - Medicine and state KW - Policy, Medical KW - Public health KW - Public health policy KW - State and medicine KW - Science and state KW - Social policy KW - Society and medical innovations KW - Medicaments KW - Medications KW - Medicine (Drugs) KW - Medicines (Drugs) KW - Pharmaceuticals KW - Prescription drugs KW - Bioactive compounds KW - Medical supplies KW - Pharmacopoeias KW - Chemotherapy KW - Materia medica KW - Pharmacology KW - Pharmacy KW - Development of drugs KW - New drug development KW - Government policy KW - Development UR - https://www.unicat.be/uniCat?func=search&query=sysid:118996804 AB - Despite a century of advances in modern medicine, as well as the rapid development of Covid vaccines, the global pharmaceutical industry has largely failed to bring to market drugs that actually cure disease. Why? And looking further ... How can government policies stimulate investment in the development of curative drugs? Is there an untapped potential for "natural medicines" in new drug discovery? How have private-public sector partnerships transformed the ways we innovate? To what extent are medicinal plant biodiversity and human health codependent? Addressing this range of increasingly critical questions, Kathryn Ibata-Arens analyzes the rise and decline of the global innovation system for new drug development and proposes a policy framework for fast-tracking the implementation of new discoveries and preparing for future pandemics. ER -